News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
113,057 Results
Type
Article (4466)
Company Profile (31)
Press Release (108559)
Multimedia
Podcasts (17)
Webinars (3)
Section
Business (40187)
Career Advice (86)
Deals (6598)
Drug Delivery (12)
Drug Development (12015)
Employer Resources (10)
FDA (2239)
Job Trends (1553)
News (55920)
Policy (4521)
Tag
2027 BioCapital Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (1)
2027 Genetown Digital (1)
2027 NextGen (2)
2027 Pharm Country Digital (1)
Academia (254)
Accelerated approval (5)
ADA (6)
Allergies (35)
Alliances (11254)
ALS (30)
Alzheimer's disease (264)
Antibody-drug conjugate (ADC) (192)
Approvals (2435)
Artificial intelligence (103)
ASCO (51)
Autoimmune disease (86)
Automation (8)
Bankruptcy (22)
Belgium (1)
Best Places to Work (1035)
BIO (21)
Biologics (9)
BIOSECURE Act (2)
Biosimilars (127)
BioSpace Insights (14)
Biotechnology (22)
Bispecific (12)
Bladder cancer (45)
Brain cancer (15)
Breast cancer (130)
Cancer (1196)
Cardiovascular disease (45)
Career advice (76)
Career pathing (1)
CAR-T (74)
CDC (4)
CDMO (21)
Celiac Disease (2)
Cell therapy (188)
Cervical cancer (14)
Clinical research (11216)
Collaboration (609)
Commercialization (13)
Company closure (4)
Compensation (189)
Complete response letters (9)
COVID-19 (378)
CRISPR (17)
CRO (1)
C-suite (319)
Cystic fibrosis (17)
Data (1642)
Denatured (6)
Depression (30)
Dermatology (21)
Diabetes (79)
Diagnostics (1139)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (104)
Drug pricing (11)
Duchenne muscular dystrophy (119)
Earnings (12829)
Editorial (6)
Employer branding (1)
Employer resources (8)
ESMO (75)
Events (14421)
Executive appointments (245)
Eye disease (1)
FDA (3020)
Fibrodysplasia Ossificans Progressiva (1)
Fragile X (1)
Friedreich's ataxia (9)
Frontotemporal dementia (2)
Funding (418)
Gene editing (54)
Generative AI (4)
Gene therapy (129)
GLP-1 (161)
Government (407)
Grass and pollen (1)
Guidances (66)
Healthcare (1798)
Hematology (21)
HIV (11)
Huntington's disease (7)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (46)
Immunology and inflammation (49)
Immuno-oncology (36)
Indications (44)
Infectious disease (432)
Inflammatory bowel disease (40)
Inflation Reduction Act (7)
Influenza (23)
Intellectual property (87)
Interviews (7)
IPO (2603)
IRA (7)
Job creations (520)
Job search strategy (70)
JPM (7)
Kidney cancer (16)
Kidney disease (21)
Labor market (13)
Layoffs (61)
Leadership (4)
Legal (1153)
Licensing (30)
Liver cancer (29)
Longevity (9)
Lung cancer (182)
Lung diease (4)
Lymphoma (78)
Machine learning (6)
Management (4)
Manufacturing (253)
Marketing (10)
MASH (33)
Medical device (1518)
Medtech (1544)
Mergers & acquisitions (4335)
Metabolic disorders (228)
mRNA (30)
Multiple sclerosis (58)
Multispecific (1)
NASH (1)
Netherlands (1)
Neurodegenerative disease (82)
Neuropsychiatric disorders (21)
Neuroscience (588)
NextGen: Class of 2026 (552)
Non-profit (217)
Now hiring (18)
Obesity (96)
Opinion (22)
Ovarian cancer (72)
Pain (68)
Pancreatic cancer (63)
Parkinson's disease (69)
Partnered (7)
Patents (154)
Patient recruitment (154)
Patient selection (26)
Peanut (3)
People (10855)
Peptides (1)
Pharmaceutical (4)
Pharmacy benefit managers (5)
Phase 1 (3600)
Phase 2 (4980)
Phase 3 (3834)
Pipeline (2449)
Policy (18)
Postmarket research (270)
Preclinical (1358)
Press Release (5)
Prostate cancer (40)
Psychedelics (5)
Radioligand (1)
Radiopharmaceuticals (49)
Rare diseases (214)
Real estate (1034)
Recruiting (5)
Regenerative medicine (6)
Regulatory (4065)
Reports (14)
Research institute (253)
Resumes & cover letters (9)
Rett syndrome (6)
RNA editing (10)
RSV (6)
Schizophrenia (39)
Series A (99)
Series B (56)
Service/supplier (2)
Sickle cell disease (12)
Special edition (3)
Spinal muscular atrophy (8)
Sponsored (4)
Startups (896)
Stomach cancer (5)
Substance use disorders (2)
Supply chain (20)
Switzerland (5)
Tariffs (2)
The Weekly (11)
Vaccines (125)
Venture capital (32)
Weight loss (49)
Women's health (41)
Women in leadership (1)
Worklife (2)
Date
Last 7 days (154)
Last 30 days (453)
Last 365 days (5176)
2026 (4335)
2025 (5002)
2024 (5634)
2023 (6493)
2022 (10333)
2021 (10033)
2020 (8741)
2019 (5765)
2018 (4462)
2017 (5219)
2016 (4687)
2015 (5721)
2014 (4301)
2013 (3747)
2012 (4159)
2011 (4247)
2010 (3790)
Location
Africa (129)
Alabama (8)
Arizona (34)
Arkansas (1)
Asia (24568)
Australia (2696)
California (3089)
Canada (852)
China (698)
Colorado (88)
Connecticut (44)
Delaware (28)
Europe (17065)
Florida (173)
Georgia (33)
Hawaii (3)
Idaho (3)
Illinois (81)
India (73)
Indiana (116)
Japan (400)
Kansas (21)
Kentucky (1)
Louisiana (3)
Maine (4)
Maryland (213)
Massachusetts (1523)
Michigan (24)
Minnesota (71)
Mississippi (1)
Missouri (9)
Nebraska (4)
Nevada (21)
New Hampshire (5)
New Jersey (756)
New York (429)
North Carolina (305)
Northern California (1514)
Ohio (72)
Oklahoma (3)
Oregon (8)
Pennsylvania (332)
Puerto Rico (2)
Rhode Island (5)
South America (149)
South Carolina (4)
Southern California (1337)
Tennessee (12)
Texas (291)
United States (7888)
Utah (45)
Vermont (1)
Virginia (89)
Washington D.C. (7)
Washington State (189)
West Virginia (1)
Wisconsin (30)
Wyoming (1)
113,057 Results for "shenzhen chipscreen biosciences ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate
October 18, 2026
·
4 min read
Press Releases
Chipscreen Biosciences Announced NMPA Approval of IND for CS43158, an AML Candidate Discovered via the AI-enabled Chemical Genomics Platform
October 12, 2026
·
3 min read
Policy
Chipscreen’s New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration through its wholly-owned subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd.
November 2, 2023
·
4 min read
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s lead innovative product Chidamide, an oral subtype-selective histone deacetylase inhibitor, combined with R-CHOP, has been officially approved by the National Medical Products Administration for treatment of previously untreated diffuse large B-cell lymphoma with positive MYC and BCL2 expression.
April 30, 2024
·
8 min read
Business
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. today announced that its wholly owned subsidiary, Eucure has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
February 27, 2023
·
5 min read
Press Releases
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
September 7, 2026
·
3 min read
Press Releases
Finance & Accounting for Bioscience West debuts in San Diego this December
Discover innovative financial strategies and expert guidance from leading bioscience finance executives at this first-ever West Coast forum.
September 18, 2026
·
1 min read
Drug Development
Chipscreen Biosciences’ Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
October 17, 2024
·
3 min read
Press Releases
Swiss Bioscience and OrganTech sign MOU to explore strategic collaboration in hair regeneration in Europe
Swiss Bioscience selected as OrganTech’s preferred strategic partner in Europe for regulatory development, GMP manufacturing, clinical research, and potential commercialization of the conditioned medium technology.
September 23, 2026
·
1 min read
Drug Development
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as “chipscreen biosciences”, stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024.
March 18, 2024
·
4 min read
1 of 11,306
Next
